ProCE Banner Activity

CheckMate 227: First-line Nivolumab + CT vs Nivolumab + Ipilimumab vs CT in Patients With NSCLC and < 1% PD-L1 Expression

Slideset Download
Conference Coverage
For patients with < 1% PD-L1 tumor expression, PFS benefit with first-line nivolumab combinations was limited to those who also had high tumor mutational burden.

Released: June 07, 2018

Expiration: June 06, 2019

No longer available for credit.

Share

Provided by

Jointly provided by the Annenberg Center for Health Sciences at Eisenhower and Clinical Care Options, LLC
ProCE Banner

Supporters

Supported by educational grants from

Amgen, Inc.

Astellas Text

AstraZeneca

Celgene

Eisai

Genentech TEXT Only

Janssen

Merck Oncology

Seagen